Single-agent irinotecan as second-line treatment for advanced gastric cancer

Simple item page
dc.contributor.buuauthorKanat, Özkan
dc.contributor.buuauthorEvrensel, Türkkan
dc.contributor.buuauthorManavoğlu, Osman
dc.contributor.buuauthorDemiray, Mutlu
dc.contributor.buuauthorKurt, Ender
dc.contributor.buuauthorGönüllü, Güzin
dc.contributor.buuauthorKıyıcı, Murat
dc.contributor.buuauthorArslan, Murat
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Medikal Onkoloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0002-9732-5340tr_TR
dc.contributor.orcid0000-0003-2501-3097tr_TR
dc.contributor.orcid0000-0002-3208-6211tr_TR
dc.contributor.researcheridAAJ-1027-2021tr_TR
dc.contributor.researcheridM-8060-2019tr_TR
dc.contributor.scopusid55881548500tr_TR
dc.contributor.scopusid6603942124tr_TR
dc.contributor.scopusid6602587152tr_TR
dc.contributor.scopusid6603631569tr_TR
dc.contributor.scopusid7006207332tr_TR
dc.contributor.scopusid6506410014tr_TR
dc.contributor.scopusid6507627491tr_TR
dc.contributor.scopusid57197925370tr_TR
dc.date.accessioned2022-03-10T10:45:09Z
dc.date.available2022-03-10T10:45:09Z
dc.date.issued2003
dc.description.abstractAim. To investigate the activity and toxicity of irinotecan (CPT-11) as a single agent in patients with advanced gastric cancer after failure of previous 5-fluorouracil-based combination chemotherapy. Patients and methods: Sixteen patients with advanced gastric received CPT-11, 350 mg/m2 every 21 days. The median age of the patients was 54.6 years; ECOG performance status was 0-1 in 14 patients and 2 in 2 patients. Dominant metastatic sites included liver, lung, lymph nodes and peritoneum. Results: No complete response was observed. Two patients (12.5%) achieved a partial response to treatment. One patient (6.25%) had a minor response. Ten patients (62.5%) had progressive disease on therapy, and 3 patients (18.75%) had stable disease. The median survival of all 16 patients was 5 months. Grade 3 neutropenia was observed in 3 patients (18.75%), grade 4 thrombocytopenia in 1 patient (6.25%), and grade 3 anemia in 1 patient (6.25%). Three patients (18.75%) suffered from grade 3 diarrhea. Conclusions: CPT-11 is moderately active and a well-tolerated regimen for selected advanced gastric cancer patients who experience disease progression after receiving first-line treatment.en_US
dc.identifier.citationKanat, O. vd. (2003). “Single-agent irinotecan as second-line treatment for advanced gastric cancer”. Tumori Journal, 89(4), 405-407.en_US
dc.identifier.endpage407tr_TR
dc.identifier.issn0300-8916
dc.identifier.issue4tr_TR
dc.identifier.pubmed14606644tr_TR
dc.identifier.scopus2-s2.0-0142137176tr_TR
dc.identifier.startpage405tr_TR
dc.identifier.urihttps://doi.org/0.1177/030089160308900411
dc.identifier.urihttps://journals.sagepub.com/doi/abs/10.1177/030089160308900411
dc.identifier.urihttp://hdl.handle.net/11452/24938
dc.identifier.volume89tr_TR
dc.identifier.wos000185505200011tr_TR
dc.indexed.pubmedPubmeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherSage Publicationsen_US
dc.relation.journalTumori Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectOncologyen_US
dc.subjectGastric canceren_US
dc.subjectIrinotecanen_US
dc.subjectSecond-line chemotherapyen_US
dc.subjectSupportive careen_US
dc.subjectPhase-IIen_US
dc.subjectMethotrexateen_US
dc.subjectCarboplatinen_US
dc.subjectPaclitaxelen_US
dc.subjectCisplatinen_US
dc.subject.emtreeCisplatinen_US
dc.subject.emtreeDoxorubicinen_US
dc.subject.emtreeFluorouracilen_US
dc.subject.emtreeIrinotecanen_US
dc.subject.emtreeLoperamideen_US
dc.subject.emtreeMitomycinen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAdvanced canceren_US
dc.subject.emtreeAgeden_US
dc.subject.emtreeAnemiaen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeClinical articleen_US
dc.subject.emtreeClinical trialen_US
dc.subject.emtreeDiarrheaen_US
dc.subject.emtreeDrug efficacyen_US
dc.subject.emtreeDrug safetyen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeLiver metastasisen_US
dc.subject.emtreeLung metastasisen_US
dc.subject.emtreeLymph node metastasisen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeMonotherapyen_US
dc.subject.emtreeMucosa inflammationen_US
dc.subject.emtreeNeutropeniaen_US
dc.subject.emtreePeritoneum metastasisen_US
dc.subject.emtreeStomach carcinomaen_US
dc.subject.emtreeSurvival timeen_US
dc.subject.emtreeThrombocytopeniaen_US
dc.subject.scopusRamucirumab; Rivoceranib; Lineen_US
dc.subject.wosOncologyen_US
dc.titleSingle-agent irinotecan as second-line treatment for advanced gastric canceren_US
dc.typeArticle

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus